Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation

British Journal of Ophthalmology

Volumn 93, Issue 10, 2009, Pages 1387-1390

  Baranano D E ^a,b,e   Kim, S J ^b,c   Edelhauser, H F ^b   Durairaj, C ^d   Kompella, U B ^d   Handa, J T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; KETOROLAC; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL RABBIT; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UVEITIS; VITREOUS BODY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INJECTIONS; KETOROLAC; LIPOPOLYSACCHARIDES; MALE; RABBITS; TREATMENT OUTCOME; UVEITIS; VITREOUS BODY;

EID: 70349973295     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.157297     Document Type: Article

References (31)

1. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol 2006;17:235-244
2. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034-8; discussion 9. (Pubitemid 30823185)
3. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy 2005;4:31-38 (Pubitemid 40584850)
4. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725-727
5. Shen WY, Constable IJ, Chelva E, et al. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 2000;238:273-282 (Pubitemid 30197964)
6. Kulkarni PS, Paterson CA. Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits. Exp Eye Res 1995;61:767-768
7. Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J Ocul Pharmacol Ther 2004;20:345-352
8. Waterbury LD, Flach AJ. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation. J Ocul Pharmacol Ther 2006;22:155-159
9. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 1996;37:613-618
10. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008;28:595-605.
11. Margalit E, Kugler LJ, Brumm MV, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci 2006;47:2093-2099
12. Lopez-Cortes LF, Pastor-Ramos MT, Ruiz-Valderas R, et al. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2001;42:1024-1028 (Pubitemid 32289799)
13. Verma MJ, Mukaida N, Vollmer-Conna U, et al. Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci 1999;40:2465-2470 (Pubitemid 29455471)
14. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934 (Pubitemid 24377783)
15. Hiscott PS, Unger WG, Grierson I, et al. The role of inflammation in the development of epiretinal membranes. Curr Eye Res 1988;7:877-892 (Pubitemid 18234064)
16. Ruiz-Moreno JM, Thillaye B, de Kozak Y. Retino-choroidal changes in endotoxininduced uveitis in the rat. Ophthalmic Res 1992;24:162-168
17. Yang P, de Vos AF, Kijlstra A. Macrophages and MHC class II positive cells in the choroid during endotoxin induced uveitis. Br J Ophthalmol 1997;81:396-401. (Pubitemid 27271858)
18. Zhang M, Xin H, Atherton SS. Murine cytomegalovirus (MCMV) spreads to and replicates in the retina after endotoxin-induced disruption of the blood-retinal barrier of immunosuppressed BALB/c mice. J Neurovirol 2005;11:365-375 (Pubitemid 41614516)
19. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450 (Pubitemid 24307211)
20. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461
21. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003;458:283-289
22. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317-1322
23. Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001;42:2338-2346 (Pubitemid 32848864)
24. Ju WK, Neufeld AH. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J Comp Neurol 2002;452:392-399 (Pubitemid 35154500)
25. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-143 (Pubitemid 40075333)
26. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598 (Pubitemid 41108858)
27. Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther 2007;23:585-590 (Pubitemid 350204684)
28. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007;56:373-379 (Pubitemid 46263075)
29. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47(1 Suppl):S203-18.
30. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998;105:397-405.
31. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281-291